The short version of Mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-15. Anything still debated is marked as such rather than presented as settled.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
== Selected publications == Araujo JV, Davidenko N, Danner M, Cameron RE, Best SM: Novel Porous scaffolds of pH Responsive Chitosan/Carrageenan-based Polyelectrolyte Complexes for Tissue Engineering. J Biomed Mater Res A. 2014 Feb 14. Pawelec KM, Husmann A, Best SM, Cameron RE: Understanding anisotropy and architecture in ice-templated biopolymer scaffolds. Mater Sci Eng C Mater Biol Appl. 2014 Apr 1;37:141-7. Pawelec KM, Husmann A, Best SM, Cameron RE: A design protocol for tailoring ice-templated scaffold structure. J R Soc Interface. 2014 Jan 8;11(92):20130958. Shepherd JH, Ghose S, Kew SJ, Moavenian A, Best SM, Cameron RE: Effect of fiber crosslinking on collagen-fiber reinforced collagen-chondroitin-6-sulfate materials for regenerating load-bearing soft tissues. J Biomed Mater Res A. 2013 Jan;101(1):176-84. Kew SJ, Gwynne JH, Enea D, Brookes R, Rushton N, Best SM, Cameron RE: Synthetic collagen fascicles for the regeneration of tendon tissue. Acta Biomater. 2012 Oct;8(10):3723-31. Grover CN, Gwynne JH, Pugh N, Hamaia S, Farndale RW, Best SM, Cameron RE: Crosslinking and composition influence the surface properties, mechanical stiffness and cell reactivity of collagen-based films. Acta Biomater. 2012 Aug;8(8):3080-90. Grover CN, Farndale RW, Best SM, Cameron RE: The interplay between physical and chemical properties of protein films affects their bioactivity. J Biomed Mater Res A. 2012 Sep;100(9):2401-11.
Short-acting compounds have a median half-life of 1–12 hours. They have few residual effects if taken before bedtime, rebound insomnia may occur upon discontinuation, and they might cause daytime withdrawal symptoms such as next day rebound anxiety with prolonged usage. Examples are brotizolam, midazolam, and triazolam. Intermediate-acting compounds have a median half-life of 12–40 hours. They may have some residual effects in the first half of the day if used as a hypnotic. Rebound insomnia, however, is more common upon discontinuation of intermediate-acting benzodiazepines than longer-acting benzodiazepines. Examples are alprazolam, estazolam, flunitrazepam, clonazepam, lormetazepam, lorazepam, nitrazepam, and temazepam. Long-acting compounds have a half-life of 40–250 hours. They have a risk of accumulation in the elderly and in individuals with severely impaired liver function, but they have a reduced severity of rebound effects and withdrawal. Examples are diazepam, clorazepate, clobazam, chlordiazepoxide, and flurazepam.
== Chemistry == Isavuconazonium comprises an N-(3-acetoxypropyl)-N-methylamino-carboxymethyl group linked through an ester moiety to the triazole nitrogen in isavuconazole. In the aquatic media of the body, the isavuconazole molecule is transformed into monohydrate.
== In animals == The Biological Value method is also used for analysis in animals such as cattle, poultry, and various laboratory animals such as rats. It was used by the poultry industry to determine which mixtures of feed were utilized most efficiently by developing chicken. Although the process remains the same, the biological values of particular proteins in humans differs from their biological values in animals due to physiological variations.
=== Catalysts === Boron trifluoride and trichloride are used as homogeneous catalysts in organic synthesis and electronics; the tribromide is used in the manufacture of diborane. Non-toxic boron ligands could replace toxic phosphorus ligands in some transition metal catalysts. Silica sulfuric acid (SiO2OSO3H) is used in organic reactions. Germanium dioxide is sometimes used as a catalyst in the production of PET plastic for containers; cheaper antimony compounds, such as the trioxide or triacetate, are more commonly employed for the same purpose despite concerns about antimony contamination of food and drinks. Arsenic trioxide has been used in the production of natural gas, to boost the removal of carbon dioxide, as have selenous acid and tellurous acid. Selenium acts as a catalyst in some microorganisms. Tellurium, its dioxide, and its tetrachloride are strong catalysts for air oxidation of carbon above 500 °C. Graphite oxide can be used as a catalyst in the synthesis of imines and their derivatives. Activated carbon and alumina have been used as catalysts for the removal of sulfur contaminants from natural gas. Titanium doped aluminium has been suggested as a substitute for noble metal catalysts used in the production of industrial chemicals.
Sources: en.wikipedia.org
=== Mid-cycle === The absence of GnSAF lowers the threshold for GnRH pulse frequency and amplitude required to stimulate the anterior pituitary to secrete LH. Concurrently, GnRH pulse frequency and amplitude increases, which allows LH secretion significantly higher than basal levels. The LH secretion most noticeable as a LH surge lasting 48 to 72 hours in the middle of the ovarian cycle. Meiosis in the dominant follicle resumes and follicle ruptures shortly after the LH surge. Ovulation can only occur if GnSAF is absent and the mid-cycle LH surge occurs.
== History == Volufralin was originated by Uppsala University in Sweden and is under development by Dicot Pharma. As of July 2026, it is in phase 2 clinical trials for erectile dysfunction and the preclinical research stage of development for premature ejaculation. The mechanism of action of the drug of indirect melanocortin MC4 receptor potentiation was not initially disclosed, but was announced by its developer in December 2025. The exact chemical structure of volufralin was not initially disclosed, aside from it being related to the libiguins. However, in July 2026, the generic name of volufralin and its structure were published.
nebeprisikiškiakopūstlapiaujančiuosiuose – "in those, of masculine gender, who aren't gathering enough wood sorrel's leaves by themselves anymore." – the plural locative case of past iterative active participle of verb kiškiakopūstlapiauti meaning "to pick wood-sorrels' leaves" (leaves of edible forest plant with sour taste, word by word translation "rabbit cabbage"). The word is attributed to software developer / writer Andrius Stašauskas.
Gene targeting techniques, which creates double-stranded breaks and takes advantage on the cells natural homologous recombination repair systems, have been developed to target insertion to exact locations. Genome editing uses artificially engineered nucleases that create breaks at specific points. There are four families of engineered nucleases: meganucleases, zinc finger nucleases, transcription activator-like effector nucleases (TALENs), and the Cas9-guideRNA system (adapted from CRISPR). TALEN and CRISPR are the two most commonly used and each has its own advantages. TALENs have greater target specificity, while CRISPR is easier to design and more efficient.
==== Micronutrient undernutrition ==== Micronutrient undernutrition results from insufficient intake of vitamins and minerals. Worldwide, deficiencies in iodine, Vitamin A, and iron are the most common. Children and pregnant women in low-income countries are at especially high risk for micronutrient deficiencies. Anemia is most commonly caused by iron deficiency, but can also result from other micronutrient deficiencies and diseases. Vitamin B12 deficiency may cause anemia, but not in all cases, in which may result in changes in consciousness or thinking, or even irreversible neurological damage. This condition can have major health consequences. It is possible to have overnutrition simultaneously with micronutrient deficiencies; this condition is termed the double burden of malnutrition.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.